Clinical Trials Browser

OTHER × ON 01910 × 1 year × Clear all

NCT05764395 2026-04-27

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2 Active not recruiting

Melanoma

NCT03786237 2026-02-24

Rigosertib for RDEB-SCC

Phase 1/2 Completed

Carcinoma, Squamous Cell, Epidermolysis Bullosa Dystrophica